TriSalus Life Sciences, Inc.(TLSI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,524 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TLSI Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for TriSalus Life Sciences, Inc. (TLSI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLSI at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,524 of 2,962 stocks — the bottom half of the AI-ranked universe. TLSI scores in the top quartile across revenue growth (90.8). Areas of concern include balance sheet strength (3.1) and revenue scale (8.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TriSalus Life Sciences, Inc. reports quarterly revenue of $11.4M, net income of $-9.2M, free cash flow of $-10.2M. Top institutional holders of TLSI by reported 13-F value include First Light Asset Management, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TLSI trades on the Nasdaq exchange and files with the SEC under CIK 1826667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TriSalus Life Sciences, Inc. directly from SEC EDGAR. TriSalus Life Sciences, Inc.'s 13F Pro composite quality score has ranged between 27 and 33 since 2025, currently 29.7 — a stable long-term trajectory across 51 quarterly and live scoring snapshots.
Revenue
Q2 2026
$11.4M
Net Income
Q2 2026
$-9.2M
Free Cash Flow
Q2 2026
$-10.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+53.4% YoYNet Income
-30.6% YoYOperating Income
+25.5% YoYEPS (Diluted)
-40.5% YoYTotal Assets
+47.4% YoYTotal Debt
+49.6% YoYOp. Cash Flow
+55.9% YoYFree Cash Flow
+54.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $45.2M +53.4% | $29.4M +59.0% | $18.5M +49.3% | $12.4M | — | — |
| Net Income | $-39.2M -30.6% | $-30.0M +49.4% | $-59.4M -25.8% | $-47.2M -1089.8% | $4.8M | — |
| Operating Income | $-26.9M +25.5% | $-36.2M +33.6% | $-54.5M -49.5% | $-36.4M -1098.4% | $-3.0M | — |
| EPS (Diluted) | $-1.84 -40.5% | $-1.31 +80.6% | $-6.77 +95.8% | $-161.55 | — | — |
| Total Assets | $35.3M +47.4% | $24.0M -2.5% | $24.6M +11.8% | $22.0M -91.2% | $250.5M -0.6% | $252.0M |
| Total Debt | $33.0M +49.6% | $22.1M | $0.00 | — | — | — |
| Operating Cash Flow | $-18.0M +55.9% | $-40.8M +19.2% | $-50.6M -56.5% | $-32.3M -1759.1% | $-1.7M | — |
| Free Cash Flow | $-18.9M +54.0% | $-41.2M +19.5% | $-51.2M -55.2% | $-33.0M | — | — |
Get alerted when TLSI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for TriSalus Life Sciences, Inc. including:
Top Institutional Holders of TLSI
First Light Asset Management, LLC
$29.8M6,552,491 shBlackRock, Inc.
$12.1M2,659,218 shVANGUARD CAPITAL MANAGEMENT LLC
$7.9M1,729,385 shCerity Partners LLC
$7.3M1,603,538 shGEODE CAPITAL MANAGEMENT, LLC
$5.4M1,190,067 shNantahala Capital Management, LLC
$4.5M1,000,000 shGILDER GAGNON HOWE & CO LLC
$3.9M850,081 shSTATE STREET CORP
$2.8M610,963 shWHITE PINE CAPITAL LLC
$2.5M547,577 shTHOMPSON SIEGEL & WALMSLEY LLC
$2.4M536,534 sh
| Fund | Value | Shares |
|---|---|---|
| First Light Asset Management, LLC | $29.8M | 6,552,491 |
| BlackRock, Inc. | $12.1M | 2,659,218 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.9M | 1,729,385 |
| Cerity Partners LLC | $7.3M | 1,603,538 |
| GEODE CAPITAL MANAGEMENT, LLC | $5.4M | 1,190,067 |
| Nantahala Capital Management, LLC | $4.5M | 1,000,000 |
| GILDER GAGNON HOWE & CO LLC | $3.9M | 850,081 |
| STATE STREET CORP | $2.8M | 610,963 |
| WHITE PINE CAPITAL LLC | $2.5M | 547,577 |
| THOMPSON SIEGEL & WALMSLEY LLC | $2.4M | 536,534 |
Companies Similar to TLSI
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
NeuroPace Inc
KORU Medical Systems, Inc.
Axogen, Inc.
Apyx Medical Corp
Crinetics Pharmaceuticals, Inc.
ESTABLISHMENT LABS HOLDINGS INC.
Vanda Pharmaceuticals Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TLSI on your watchlist
Track score changes the day TriSalus Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TLSI a good stock to buy?
13F Pro's AI-powered analysis of TriSalus Life Sciences, Inc. (TLSI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TLSI are available on the TLSI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TLSI is classified as a small company.
Which hedge funds own TLSI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TLSI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TriSalus Life Sciences, Inc.'s investment landscape.